ACUR Key Stats
- Acura Pharmaceuticals' CEO Discusses Q3 2013 Results - Earnings Call Transcript Seeking Alpha Nov 5
- Pre-Open Stock Movers 11/05: (CYTX) (ENDP) (GTAT) Higher; (BSFT) (IMGN) (LF) Lower (more...) Street Insider Nov 5
- After-Hours Stock Movers 11/04: (ACUR) (FN) (PXD) Higher; (BSFT) (ANAD) (LF) Lower (more...) Street Insider Nov 4
- Acura Pharmaceuticals Announces Third Quarter 2013 Financial Results noodls Nov 4
- Acura Pharmaceuticals Announces Distribution of Nexafed(R) by Rite Aid Pharmacies Nov 4
- Acura Pharmaceuticals (ACUR) Higher as Rite Aid to Carry NEXAFED Street Insider Nov 4
- ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an Nov 4
- ACURA PHARMACEUTICALS, INC Files SEC form 10-Q, Quarterly Report Nov 4
- Q3 2013 Acura Pharmaceuticals, Inc. Earnings Release - After Market Close Nov 4
- Acura Pharmaceuticals to Host Third Quarter 2013 Financial Results Conference Call on November 5, 2013 noodls Oct 29
ACUR Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Acura Pharmaceuticals is down 2.27% over the last year vs S&P 500 Total Return up 30.02%, Actavis up 82.98%, and Durect up 65.12%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for ACUR
Pro Strategies Featuring ACUR
Did Acura Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Acura Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in the research, development and manufacture of product candidates providing abuse deterrent features and benefits.